Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes Results of a Randomized Pharmacodynamic Study in a Feasibility Investigation of Rapid Genetic Testing

被引：31

作者：

Franchi, Francesco ^{[1
]}

Rollini, Fabiana ^{[1
]}

Rivas, Jose ^{[1
]}

Rivas, Andrea ^{[1
]}

Agarwal, Malhar ^{[1
]}

Briceno, Maryuri ^{[1
]}

Wali, Mustafa ^{[1
]}

Nawaz, Ahmed ^{[1
]}

Silva, Gabriel ^{[1
]}

Shaikh, Zubair ^{[1
]}

Maailiki, Naji ^{[1
]}

Been, Latonya ^{[1
]}

Pineda, Andres M. ^{[1
]}

Suryadevara, Siva ^{[1
]}

Soffer, Daniel ^{[1
]}

Zenni, Martin M. ^{[1
]}

Bass, Theodore A. ^{[1
]}

Angiolillo, Dominick J. ^{[1
]}

机构：

[1] Univ Florida, Coll Med Jacksonville, 655 West 8th St, Jacksonville, FL 32209 USA

来源：

JACC-BASIC TO TRANSLATIONAL SCIENCE | 2020年 / 5卷 / 05期

关键词：

genotyping; percutaneous coronary intervention; pharmacodynamics; prasugrel; ticagrelor; PERCUTANEOUS CORONARY INTERVENTION; GUIDED ANTIPLATELET THERAPY; PLATELET REACTIVITY; CLINICAL-OUTCOMES; CARDIOVASCULAR OUTCOMES; TROPICAL-ACS; CLOPIDOGREL; POLYMORPHISMS; IMPACT; RESPONSIVENESS;

D O I：

10.1016/j.jacbts.2020.02.009

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The feasibility of rapid genetic testing in patients undergoing percutaneous coronary intervention (PCI) and the comparison of the pharmacodynamic effects of prasugrel versus ticagrelor among carriers of cytochrome P450 2C19 loss-of-function alleles treated with PCI has been poorly explored. Rapid genetic testing using the Spartan assay was shown to be feasible and provides results in a timely fashion in a real-world setting of patients undergoing coronary angiography (n = 781). Among patients (n = 223, 28.5%), carriers of at least 1 loss-of-function allele treated with PCI (n = 65), prasugrel, and ticagrelor achieve similar levels of platelet inhibition. (A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function [NCT02065479]) (C) 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.

引用

页码：419 / 428

页数：10

共 44 条

[11] A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI
Claassens, Daniel M. F.
Vos, Gerrit J. A.
Bergmeijer, Thomas O.
Hermanides, Renicus S.
van 't Hof, Arnoud W. J.
van der Harst, Pim
Barbato, Emanuele
Morisco, Carmine
Gin, Richard M. Tjon Joe
Asselbergs, Folkert W.
Mosterd, Arend
Herrman, Jean-Paul R.
Dewilde, Willem J. M.
Janssen, Paul W. A.
Kelder, Johannes C.
Postma, Maarten J.
de Boer, Anthonius
Boersma, Cornelis
Deneer, Vera H. M.
ten Berg, Jurrien M.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (17) : 1621 - 1631
[12] Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy
Empey, Philip E.
Stevenson, James M.
Tuteja, Sony
Weitzel, Kristin W.
Angiolillo, Dominick J.
Beitelshees, Amber L.
Coons, James C.
Duarte, Julio D.
Franchi, Francesco
Jeng, Linda J. B.
Johnson, Julie A.
Kreutz, Rolf P.
Limdi, Nita A.
Maloney, Kristin A.
Obeng, Aniwaa Owusu
Peterson, Josh F.
Petry, Natasha
Pratt, Victoria M.
Rollini, Fabiana
Scott, Stuart A.
Skaar, Todd C.
Vesely, Mark R.
Stouffer, George A.
Wilke, Russell A.
Cavallari, Larisa H.
Lee, Craig R.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 104 (04) : 664 - 674
[13] European Medicines Agency, SUMM PROD CHAR PLAV
[14] Metabolism and Disposition of the Thienopyridine Antiplatelet Drugs Ticlopidine, Clopidogrel, and Prasugrel in Humans
Farid, Nagy A.
Kurihara, Atsushi
Wrighton, Steven A.
[J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (02) : 126 - 142
[15] Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease Results of the SWAP-4 Study
Franchi, Francesco
Rollini, Fabiana
Rios, Jose Rivas
Rivas, Andrea
Agarwal, Malhar
Kureti, Megha
Nagaraju, Deepa
Wali, Mustafa
Shaikh, Zubair
Briceno, Maryuri
Nawaz, Ahmed
Moon, Jae Youn
Been, Latonya
Suryadevara, Siva
Soffer, Daniel
Zenni, Martin M.
Bass, Theodore A.
Angiolillo, Dominick J.
[J]. CIRCULATION, 2018, 137 (23) : 2450 - 2462
[16] Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study
Franchi, Francesco
Rollini, Fabiana
Aggarwal, Niti
Hu, Jenny
Kureti, Megha
Durairaj, Ashwin
Duarte, Valeria E.
Cho, Jung Rae
Been, Latonya
Zenni, Martin M.
Bass, Theodore A.
Angiolillo, Dominick J.
[J]. CIRCULATION, 2016, 134 (11) : 780 - +
[17] Novel antiplatelet agents in acute coronary syndrome
Franchi, Francesco
Angiolillo, Dominick J.
[J]. NATURE REVIEWS CARDIOLOGY, 2015, 12 (01) : 30 - 47
[18] Impact of Cytochrome P450 2C19 Loss-of-Function Polymorphism and of Major Demographic Characteristics on Residual Platelet Function After Loading and Maintenance Treatment With Clopidogrel in Patients Undergoing Elective Coronary Stent Placement
Hochholzer, Willibald
Trenk, Dietmar
Fromm, Martin F.
Valina, Christian M.
Stratz, Christian
Bestehorn, Hans-Peter
Buettner, Heinz Joachim
Neumann, Franz-Josef
[J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (22) : 2427 - 2434
[19] Tailored P2Y12 inhibitor treatment in patients undergoing non-urgent PCI-the POPular Risk Score study
Janssen, Paul W. A.
Bergmeijer, Thomas O.
Vos, Gert-Jan A.
Kelder, Johannes C.
Qaderdan, Khalid
Godschalk, Thea C.
Breet, Nicoline J.
Deneer, Vera H. M.
Hackeng, Christian M.
ten Berg, Jurrien M.
[J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 75 (09) : 1201 - 1210
[20] High on-treatment platelet reactivity with ticagrelor versus prasugrel: a systematic review and meta-analysis
Lemesle, G.
Schurtz, G.
Bauters, C.
Hamon, M.
[J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 (06) : 931 - 942

← 1 2 3 4 5 →